Pfizer begins Phase 2/3 study for COVID-19 oral antiviral in exposed adults
Fox News
Pfizer initiated a Phase 2/3 study of an investigational oral antiviral with a low dose of ritonavir to prevent COVID-19 illness, the company announced Monday.
The Phase 2/3 study called EPIC-PEP, (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis), is a randomized, double-blind, placebo-controlled trial, set to enroll up to 2,660 healthy adults ages 18 and older living with a household member with a confirmed symptomatic COVID-19 infection. Study participants will be randomly assigned to receive PF-07321332/ritonavir or a placebo twice each day for five or 10 days, per the news release. The treatment is designed to be administered early (such as the first sign or infection or awareness of exposure) while ritonavir is intended to slow the metabolism of the PF-07321332 antiviral to help fight the virus for a longer period of time.
Tranquil hot springs around the US you can visit this winter to find warmth even on the coldest days
A dip inside a hot spring can help reduce stress and pain. You don't have to take an international trip in order to reap the benefits of a hot spring, as there are plenty located right in the U.S.